Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Research & Development (2023 - 2025)

Contineum Therapeutics has reported Research & Development over the past 3 years, most recently at $12.8 million for Q4 2025.

  • Quarterly results put Research & Development at $12.8 million for Q4 2025, down 2.0% from a year ago — trailing twelve months through Dec 2025 was $51.5 million (up 34.1% YoY), and the annual figure for FY2025 was $51.5 million, up 34.1%.
  • Research & Development for Q4 2025 was $12.8 million at Contineum Therapeutics, up from $11.0 million in the prior quarter.
  • Over the last five years, Research & Development for CTNM hit a ceiling of $14.1 million in Q2 2025 and a floor of $3.6 million in Q1 2023.
  • Median Research & Development over the past 3 years was $9.6 million (2023), compared with a mean of $9.8 million.
  • Peak annual rise in Research & Development hit 114.15% in 2024, while the deepest fall reached 16.48% in 2024.
  • Contineum Therapeutics' Research & Development stood at $8.0 million in 2023, then skyrocketed by 62.44% to $13.0 million in 2024, then dropped by 2.0% to $12.8 million in 2025.
  • The last three reported values for Research & Development were $12.8 million (Q4 2025), $11.0 million (Q3 2025), and $14.1 million (Q2 2025) per Business Quant data.